No Data
No Data
Analyst Expectations For Celldex Therapeutics's Future
In the preceding three months, 5 analysts have released ratings for Celldex Therapeutics (NASDAQ:CLDX), presenting a wide array of perspectives from bullish to bearish.The following table summarizes
HC Wainwright & Co. Reiterates Buy on Celldex Therapeutics, Maintains $80 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Celldex Therapeutics (NASDAQ:CLDX) with a Buy and maintains $80 price target.
H.C. Wainwright Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Maintains Target Price $80
H.C. Wainwright analyst Joseph Pantginis maintains $Celldex Therapeutics(CLDX.US)$ with a buy rating, and maintains the target price at $80.According to TipRanks data, the analyst has a success rate
Express News | Celldex Therapeutics Inc -Embarq-Csu1 and Embarq-Csu 2 Will Enroll More Than 1800 Patients Suffering From Csu
Express News | Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients With Chronic Spontaneous Urticaria
Celldex Therapeutics(CLDX.US) Officer Sells US$608.31K in Common Stock
$Celldex Therapeutics(CLDX.US)$ Officer Martin Samuel Bates sold 17,172 shares of common stock on Jun 14, 2024 at an average price of $35.4248 for a total value of $608.31K.Source: Announcement What i